These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24165947)

  • 1. Efficient clinical trials in Japan: Bridging studies versus participation in global clinical trials.
    Shirotani M; Suwa T; Kurokawa T; Chiba K
    J Clin Pharmacol; 2014 Apr; 54(4):438-45. PubMed ID: 24165947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan.
    Uyama Y; Shibata T; Nagai N; Hanaoka H; Toyoshima S; Mori K
    Clin Pharmacol Ther; 2005 Aug; 78(2):102-13. PubMed ID: 16084844
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan.
    Shirotani M; Kurokawa T; Chiba K
    J Clin Pharmacol; 2014 Jul; 54(7):753-64. PubMed ID: 24496890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
    Tanaka M; Nagata T
    Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Globalization of clinical trials].
    Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan.
    Ueno T; Asahina Y; Tanaka A; Yamada H; Nakamura M; Uyama Y
    Clin Pharmacol Ther; 2014 May; 95(5):533-41. PubMed ID: 24213186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of the Bridging Strategy for the Development of New Drugs in Oncology to Avoid Drug Lag.
    Kogure S; Koyama N; Hidaka S
    J Clin Pharmacol; 2017 Nov; 57(11):1479-1490. PubMed ID: 28628225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects.
    Ando Y; Uyama Y
    J Biopharm Stat; 2012 Sep; 22(5):977-87. PubMed ID: 22946944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delays in new drug applications in Japan and industrial R&D strategies.
    Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A consistency approach to evaluation of bridging studies and multi-regional trials.
    Tsou HH; Chien TY; Liu JP; Hsiao CF
    Stat Med; 2011 Jul; 30(17):2171-86. PubMed ID: 21590701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.
    Piana C; Kliphuis E; Della Pasqua O
    Clin Trials; 2013 Apr; 10(2):269-79. PubMed ID: 23335676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Participation to international registration trials--from the investigator's standpoint].
    Ohtsu A
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of regional treatment effect in a multiregional clinical trial.
    Tsong Y; Chang WJ; Dong X; Tsou HH
    J Biopharm Stat; 2012 Sep; 22(5):1019-36. PubMed ID: 22946947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between drug lag and factors associated with clinical trials in Japan.
    Ohwaki K; Nakabayashi T
    J Clin Pharm Ther; 2014 Dec; 39(6):649-52. PubMed ID: 25200123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The history of developing anticancer Drugs and their evaluation guidelines in Japan].
    Maeda H; Kurokawa T
    Yakushigaku Zasshi; 2014; 49(2):196-204. PubMed ID: 25799841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?
    Chiba K; Yoshitsugu H; Kyosaka Y; Iida S; Yoneyama K; Tanigawa T; Fukushima T; Hiraoka M
    J Clin Pharmacol; 2014 May; 54(5):483-94. PubMed ID: 24242979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of an anticancer drug in Japan based on a new clinical trial system].
    Nakashima H; Nakano S
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):287-94. PubMed ID: 9492818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consistency assessment with global and bridging development strategies in emerging markets.
    Li G; Chen J; Quan H; Shentu Y
    Contemp Clin Trials; 2013 Nov; 36(2):687-96. PubMed ID: 23702264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size considerations for Japanese patients in a multi-regional trial based on MHLW guidance.
    Quan H; Zhao PL; Zhang J; Roessner M; Aizawa K
    Pharm Stat; 2010; 9(2):100-12. PubMed ID: 19499510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.